CP-601927   Click here for help

GtoPdb Ligand ID: 9056

Synonyms: CP 601927 | CP-601,927
Compound class: Synthetic organic
Comment: CP-601927 is an orally available, CNS‐penetrant, high affinity, selective, investigational partial agonist of the nicotinic acetylcholine (nAch) receptor α4β2 [1], developed for its potential in several central nervous system conditions [3]. CP-601927 was investigated for its potential to augment antidepressant treatment in patients with major depressive disorder [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 12.03
Molecular weight 227.09
XLogP 2.35
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES FC(c1ccc2c(c1)C1CNCC2C1)(F)F
Isomeric SMILES FC(c1ccc2c(c1)[C@H]1CNC[C@@H]2C1)(F)F
InChI InChI=1S/C12H12F3N/c13-12(14,15)9-1-2-10-7-3-8(6-16-5-7)11(10)4-9/h1-2,4,7-8,16H,3,5-6H2/t7-,8+/m0/s1
InChI Key RNOBTWYQAWEZHH-JGVFFNPUSA-N
No information available.
Summary of Clinical Use Click here for help
A Phase 2 clinical trial of CP-601927 as an adjunct to antidepressant therapy in patients with major depressive disorder (NCT01098240) was terminated and development has not progressed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01098240 A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression Phase 2 Interventional Pfizer